Cancer News and Research

Latest Cancer News and Research

Novel drug therapy treats brain diseases

Pankaj Karande, a Rensselaer Polytechnic Institute assistant professor of chemical and biological engineering, is among a new generation of scientists and engineers developing exciting and novel new techniques to treat some of the most complex brain illnesses, including Alzheimer's disease, Parkinson's disease, traumatic brain injury, and brain cancer.

8 Dec 2010

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

The sun's ultraviolet light activates an enzyme that helps skin cancer cells survive and proliferate, researchers report.

8 Dec 2010

Low-dose aspirin enhances fecal occult blood test performance for detecting colorectal cancer

Use of low-dose aspirin prior to a newer type of fecal occult blood test is associated with a higher sensitivity for detecting advanced colorectal tumors, compared to no aspirin use, according to a study in the December 8 issue of JAMA.

8 Dec 2010

UC researchers launch clinical trial to study post-stroke brain injury

The largest clinical trial of therapeutic brain cooling after stroke has launched, led by researchers at the University of California, San Diego, the University of Texas Health Science Center at Houston, and at Cedars-Sinai Medical Center in Los Angeles. This study looks at whether hypothermia can safely be used in elderly stroke patients.

8 Dec 2010

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Case Western Reserve University School of Medicine faculty members are reaping the rewards of funding from the National Institutes of Health, in the form of grants and contracts. The funding totals more than $6.4 million for four different research endeavors.

8 Dec 2010

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the Company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma.

8 Dec 2010

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

8 Dec 2010

Children's Hospital LA investigators elected into the Society for Pediatric Research

Three investigators from The Saban Research Institute of Children's Hospital Los Angeles have been elected into the prestigious Society for Pediatric Research. Their election to this Society represents peer recognition of their research achievements in pediatrics.

8 Dec 2010

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.

8 Dec 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

Cephalon, Inc. and Mesoblast Limited, today announced they have entered into a strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems.

8 Dec 2010

NIH awards Scripps Research $2.35M to study new treatment for obesity

The Scripps Research Institute has been awarded a $2.35 million grant from the National Institutes of Health to study a new way of treating obesity as part of a national consortium with the Dana-Farber Cancer Institute.

8 Dec 2010

Concentrated nicotine in E-cigarattes poses unknown risks to consumers

What do some pesticides and "electronic cigarettes" have in common? According to a new report published in the American Journal of Public Health, the answer is unregulated concentrations of nicotine that may pose unknown risks to consumers who are exposed to them.

8 Dec 2010

Humble aspirin reduces cancer death rates

A new study has shown aspirin cuts down the death rates from a range of cancers. The study reviewed data from eight previous trials involving more than 25,000 patients found that those who took just 75mg of aspirin a day (one-eighth of a normal dose) could reduce their death rates from cancer by 21% with benefits continuing long after patients stopped taking the pill.

7 Dec 2010

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Abbott and Bristol-Myers Squibb Company today announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone.

7 Dec 2010

$Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL$

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

7 Dec 2010

Inergetics, Muscle Maker Grill sign Product Development Agreement

Inergetics, Inc., a leader in targeted product development for the Clinical Nutrition and Sports Supplement Markets, today announced that the Company has entered into a Product Development Agreement with Muscle Maker Grill, one of the country's fastest growing health-food franchises, to be the exclusive provider of "Muscle Maker Ultra Pro, powered by Inergetics," a powdered proprietary nutritional product to be used in various platforms in Muscle Maker Grill restaurants.

7 Dec 2010

John Theurer Cancer Center presents research findings at ASH meeting

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings presented at the annual meeting of the American Society of Hematology taking place December 4-7, 2010 in Orlando, Florida. The ASH meeting is the world's leading scientific gathering of hematologists and hematology researchers.

7 Dec 2010

$Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010$

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

EntreMed, Inc., today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology Annual Meeting being held December 4-7 in Orlando, Florida.

7 Dec 2010

Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer

Halozyme Therapeutics, Inc. today announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase).

7 Dec 2010

$Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma$

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

7 Dec 2010

Cancer News and Research

Latest Cancer News and Research

Novel drug therapy treats brain diseases

Ultraviolet light activates enzyme that helps skin cancer cells survive, proliferate: Researchers

Low-dose aspirin enhances fecal occult blood test performance for detecting colorectal cancer

UC researchers launch clinical trial to study post-stroke brain injury

Case Western Reserve School of Medicine researchers receive NIH grant for four research endeavors

Immunomedics reports CD22 antibody produced significant anti-tumor response

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Children's Hospital LA investigators elected into the Society for Pediatric Research

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

Cephalon, Mesoblast to develop, commercialize novel adult MPC therapeutics

NIH awards Scripps Research $2.35M to study new treatment for obesity

Concentrated nicotine in E-cigarattes poses unknown risks to consumers

Humble aspirin reduces cancer death rates

Positive interim results from elotuzumab Phase 1b/2 study in relapsed multiple myeloma

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Inergetics, Muscle Maker Grill sign Product Development Agreement

John Theurer Cancer Center presents research findings at ASH meeting

Interim results from Phase 1 study of ENMD-2076 in refractory MM patients presented at ASH 2010

Roche completes enrollment in Herceptin SC Phase 3 trial for HER2-positive breast cancer

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in